

Nucleotide precursors prevent folic acid-resistant neural tube defects in the mouse

Kit-Yi Leung,* Sandra C. P. De Castro,* Dawn Savery, Andrew J. Copp and Nicholas D. E. Greene*

Neural Development Unit and Birth Defects Research Centre, Institute of Child Health, University College London, UK

*These authors contributed equally to this work.

Correspondence to: Nicholas D. E. Greene
Neural Development Unit,
Newlife Birth Defects Research Centre,
UCL Institute of Child Health,
30 Guilford Street, London, WC1N 1EH
E-mail: n.greene@ucl.ac.uk

Closure of the neural tube during embryogenesis is a crucial step in development of the central nervous system. Failure of this process results in neural tube defects, including spina bifida and anencephaly, which are among the most common birth defects worldwide. Maternal use of folic acid supplements reduces risk of neural tube defects but a proportion of cases are not preventable. Folic acid is thought to act through folate one-carbon metabolism, which transfers one-carbon units for methylation reactions and nucleotide biosynthesis. Hence suboptimal performance of the intervening reactions could limit the efficacy of folic acid. We hypothesized that direct supplementation with nucleotides, downstream of folate metabolism, has the potential to support neural tube closure. Therefore, in a mouse model that exhibits folic acid-resistant neural tube defects, we tested the effect of specific combinations of pyrimidine and purine nucleotide precursors and observed a significant protective effect. Labelling in whole embryo culture showed that nucleotides are taken up by the neurulating embryo and incorporated into genomic DNA. Furthermore, the mitotic index was elevated in neural folds and hindgut of treated embryos, consistent with a proposed mechanism of neural tube defect prevention through stimulation of cellular proliferation. These findings may provide an impetus for future investigations of supplemental nucleotides as a means to prevent a greater proportion of human neural tube defects than can be achieved by folic acid alone.

Keywords: neural tube defects; spina bifida; embryo; nucleotides; *curly tail*

Abbreviations: FOCM = folate one-carbon metabolism; GMP = guanosine monophosphate

Introduction

Closure of the neural tube is an essential step in development of the CNS (Copp and Greene, 2010). Failure results in neural tube defects, including spina bifida and anencephaly, severe congenital malformations affecting 0.5–2 per 1000 pregnancies worldwide (Mitchell, 2005). Owing to their occurrence during early development and associated difficulties of diagnosis and remediation, primary prevention is the optimal therapeutic approach. Prevention of neural tube

defects became a realistic proposition following the finding that maternal supplementation with folic acid significantly reduces the rate of recurrence, following an affected pregnancy (Smithells *et al.*, 1980; Wald *et al.*, 1991). Consequently, folic acid supplements are recommended before pregnancy. Implementation of food fortification has been associated with reduced neural tube defect prevalence in several countries (Mills and Signore, 2004; Ricks *et al.*, 2012). Nevertheless, data from clinical trials, epidemiological studies and reported occurrences of sequential affected pregnancies in some

Received February 12, 2013. Revised May 8, 2013. Accepted June 4, 2013. Advance Access publication August 8, 2013

© The Author(s) 2013. Published by Oxford University Press on behalf of the Guarantors of Brain.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

individuals despite use of folic acid all show that a proportion of neural tube defects are unresponsive to folic acid (Wald *et al.*, 1991; Blom *et al.*, 2006; Mosley *et al.*, 2009). Moreover, in the fortified US population, there is no apparent benefit of additional supplement usage, suggesting that simply increasing dosage may not achieve significant further protection (Mosley *et al.*, 2009).

Overall, the relationship between folate status and neural tube defect susceptibility is not well understood, but genetically-determined abnormalities of folate one-carbon metabolism (FOCM) appear to be risk factors. For example, variants in *MTHFR*, *MTHFD1L* and genes encoding the glycine cleavage system (*GLDC* and *AMT*) have been associated with predisposition to neural tube defects (Blom *et al.*, 2006; Greene *et al.*, 2009; Parle-McDermott *et al.*, 2009; Narisawa *et al.*, 2012). Furthermore, a proportion of neural tube defect-derived cell lines exhibit apparent abnormalities of FOCM, indicated by diminished thymidylate biosynthesis (Dunlevy *et al.*, 2007). In mice, loss of function models of *Amt* and *Mthfd1L* exhibit neural tube defects, as do *Shmt* null embryos when under conditions of maternal dietary folate-deficiency (Beaudin *et al.*, 2011; Narisawa *et al.*, 2012; Momb *et al.*, 2013).

FOCM comprises a complex network of reactions with several outputs, including provision of one-carbon units for methylation reactions and nucleotide biosynthesis (Blom *et al.*, 2006; Stover, 2009). One possibility is that some neural tube defects may be resistant to folic acid prevention owing to suboptimal activity of the intervening reactions required to mediate its biological activity. It has been proposed that the protective effect of folic acid may be mediated through an epigenetic mechanism, involving enhanced DNA and/or histone methylation. An alternative, although not exclusive, hypothesis envisages the key requirement for FOCM in neural tube closure to involve provision of nucleotides to sustain rapid cellular proliferation in the neurulating embryo. This raised the question of whether direct supplementation with nucleotides could influence neural tube closure.

We tested the potential effect of nucleotide supplementation in the *curly tail* (*ct*) mouse, a well-established model for human neural tube defects (Van Straaten and Copp, 2001). The major *curly tail* gene corresponds to a hypomorphic allele of the transcription factor *Grhl3*, resulting in diminished messenger RNA expression, and neural tube defects can be rescued by transgenic overexpression of *Grhl3* (Gustavsson *et al.*, 2007). The frequency of spina bifida and exencephaly in the *curly tail* strain is influenced by environmental factors and genetic background, a recently identified modifier gene being lamin B1 (Neumann *et al.*, 1994; De Castro *et al.*, 2012). Importantly, there is no protective effect of folic acid and the *curly tail* strain therefore provides a model for resistant neural tube defects in which to test alternative treatments.

Materials and methods

Mice and supplementation

Curly tail mice were maintained as a closed random-bred colony (Van Straaten and Copp, 2001). Experimental litters were generated by overnight mating, with the day of finding a copulation plug designated

embryonic Day 0.5. Maternal supplementation was performed daily from Days 7.5–10.5. Treatment comprised intraperitoneal injection with stock solutions (in sterile water), containing each reagent at a final concentration of 2 mg/ml, to a dosage of 20 mg/kg. Doses were based on previous studies of thymidine treatment in neurulation-stage embryos (Wlodarczyk *et al.*, 2006; Burren *et al.*, 2008). Treatments were: control (water only); thymidine + adenine; thymidine + hypoxanthine; thymidine + GMP (guanosine monophosphate); thymidine only; and adenine only (all reagents from Sigma). GMP was used instead of guanine owing to solubility considerations in preparing solutions for injection. Animal studies were carried out under regulations of the Animals (Scientific Procedures) Act 1986 of the UK Government, and in accordance with guidance issued by the Medical Research Council, UK in 'Responsibility in the Use of Animals for Medical Research' (1993).

Collection of embryos

Litters were dissected from the uterus at Days 11.5–13.5, in Dulbecco's modified Eagle's medium containing 10% foetal calf serum and assessed for presence of neural tube defects under a light microscope. Any resorptions were recorded. Crown-rump length was measured using an eyepiece graticule.

Incorporation of nucleotides *in utero* and in embryo culture

Embryos were explanted at Day 9.5 and cultured for 24 h in rat serum as described previously (Cockroft 1990; Greene *et al.*, 2003), in the presence of ^3H -thymidine, ^3H -hypoxanthine or ^3H -adenine (at 1 or 2 $\mu\text{Ci/ml}$). Genomic DNA was isolated and incorporation of ^3H determined by scintillation counting as described previously (Dunlevy *et al.*, 2007). DNA concentration was determined by NanoDrop.

Proliferation analysis

Immunohistochemistry for phosphohistone H3 was performed on transverse 7- μm sections at the axial level of the closing neural folds (5–7 sections per embryo) in embryos at Day 10.5 (28–31 somites) as described previously (Gustavsson *et al.*, 2007). Primary and secondary antibodies were anti-phosphohistone H3 (1:250, Millipore) and Alexa Fluor[®] 488-conjugated anti-rabbit (1:500, Invitrogen). For nuclear staining, cells were incubated with Hoechst (1:2000 in PBS). Fluorescent images were collected on an Axiophot microscope (Zeiss) with a DC500 camera (Leica), using FireCam software (Leica). Images were analysed using the Cell Counter plugin of ImageJ software (U.S. National Institutes of Health). Cells in mitosis were scored by visual inspection of pH3-positive cells.

Statistical analysis

Statistical analysis was carried out using SigmaStat (version 3.5; Systat Software Inc). Proportions were compared by z-test. Comparisons of mean values were made by t-test or by one-way ANOVA with pairwise analysis by Holm-Sidak test.

Results

FOCM supplies one-carbon units in pyrimidine production during biosynthesis of thymidine monophosphate (Fig. 1A) and at two




Figure 2 Nucleotide supplementation prevents neural tube defects. The range of phenotypes among control and treated embryos includes (A) unaffected with straight tail (ST), (B) tail flexion defect/*curly tail* (CT) and (C) spina bifida (SB) with *curly tail*. Exencephaly (EX) can occur in isolation or with *curly tail* or spina bifida. Representative untreated *curly tail* embryos at embryonic Day 15.5 are shown. The frequency of spina bifida (D) was significantly lower among offspring of mice supplemented with thymidine + adenine ($n = 88$ embryos) or thymidine + GMP ($n = 80$) than among controls ($n = 187$ embryos; $*P < 0.01$; z-test). There was a trend towards reduced spina bifida frequency among embryos exposed to thymidine (Thy) only ($n = 74$) or thymidine + hypoxanthine ($n = 64$) but this was non-significant, whereas adenine (Ade) only ($n = 60$) had no effect. There was a significantly higher frequency of straight tails among offspring of mice supplemented with thymidine, thymidine + adenine or thymidine + GMP than among control litters ($*P < 0.01$, $***P < 0.001$; z-test), correlating with reduced rates of spina bifida in these groups. (E) The frequency of exencephaly (cranial neural tube defects) was 6.8% among embryos from control litters. Among embryos exposed to thymidine only, thymidine + adenine or thymidine + GMP there was a trend towards reduced frequency of exencephaly (2.7%, 3.0% and 2.5%, respectively). Thy = thymidine; Ade = adenine; Hyp = hypoxanthine.

As supplemental nucleotides are used in DNA synthesis, we hypothesized that the mechanism underlying prevention of neural tube defects in *curly tail* embryos involves enhanced proliferation.

We therefore analysed cell proliferation at Day 10.5, at the axial level of the closing spinal neural folds (Fig. 3A–C) and observed a significant increase in the mitotic index in the hindgut and neural folds of treated embryos compared with controls (Fig. 3D). Importantly, there was a 1.63-fold increase in hindgut mitotic index, but only a 1.39-fold increase in neuroepithelial mitotic

activity. This proportionally greater effect of nucleotide supplementation on hindgut proliferation is expected to minimize the dorsal–ventral growth imbalance that is known to hamper neural fold closure in *curly tail* embryos. Moreover, the increase in mitotic index that we observed in the hindgut is similar to the 1.7-fold increase observed in *curly tail* embryos whose spina bifida was rescued by a *Grhl3* transgene (Gustavsson *et al.*, 2007). Taken together, these findings suggest that enhanced proliferation underlies the protective effect of supplemental nucleotides. Measurement of embryo size at Day 13.5, following cessation of

treatment at Day 10.5, did not reveal a long-term effect of treatment on overall growth (Fig. 3E).

Discussion

Defective thymidylate biosynthesis has been implicated in neural tube defects in humans and mouse models (Fleming and Copp, 1998; Dunlevy *et al.*, 2007; Beaudin *et al.*, 2011), suggesting that adequate supply of nucleotides for cellular proliferation is essential

Table 1 Litter size and resorption rate is not affected by nucleotide supplementation

Treatment	No. litters	Litter size (live embryos)	Resorptions per litter
Control	15	6.9 ± 0.5	0.6 ± 0.3
Thy + Ade	14	7.1 ± 0.4	0.2 ± 0.1
Thy + Hyp	8	8.0 ± 0.7	0.1 ± 0.1
Thy + GMP	9	8.9 ± 0.6	0.3 ± 0.2
Ade only	8	7.5 ± 0.7	0.8 ± 0.3
Thy only	10	7.4 ± 0.8	0.9 ± 0.4

The number of live embryos in each litter was recorded, together with the presence of any dead embryos or resorptions. Data are expressed as mean ± SEM. There was no statistically significant difference between treatments in the litter size or the number of dead/resorbed embryos per litter (one-way ANOVA). Thy = thymidine; Ade = adenosine; Hyp = hypoxanthine.

for neural tube closure. Supplementation with thymidine alone had minimal effect on spina bifida in the current study or in other mouse models (Włodarczyk *et al.*, 2006; Burren *et al.*, 2008). In contrast, the significant protective effect of concurrent administration of adenine or GMP with thymidine suggests that provision of both pyrimidine and purine precursors effectively stimulates proliferation.

Folic acid provides a key tool in the prevention of neural tube defects. However, to mediate bioactivity supplemental folic acid must be metabolized through multiple reactions, defects in which could explain lack of response in some individuals. Downstream intervention using nucleotide precursors could potentially circumvent a scenario in which folic acid cannot ameliorate some FOCM-related neural tube defects owing to defects in the intervening enzymes required to metabolize folic acid. It is unclear whether the lack of protective effect of folic acid in the *curly tail* model reflects an underlying defect in FOCM. Nevertheless, *curly tail* embryos are sensitive to folate status, developing cranial neural tube defects at increased frequency under conditions of dietary folate deficiency (Burren *et al.*, 2010). Moreover, in comparison with wild-types, *curly tail* embryos display abnormalities in levels of methylation cycle intermediates, including increased abundance of *S*-adenosylhomocysteine (de Castro *et al.*, 2010). Impaired methylation is unlikely to contribute to neural tube defects in *curly tail* embryos, as the frequency of defects is not exacerbated in *ct/ct; Mthfr^{-/-}* double mutant embryos (de Castro *et al.*, 2010). Nevertheless, altered levels of methylation cycle intermediates may reflect perturbation of FOCM.




Figure 3 Supplemental nucleotides stimulate cellular proliferation. (A–D) At Day 10.5 (E10.5), during spinal neural tube closure, the mitotic index was determined at the level of the closure point of the neural folds at the posterior neuropore (boxed in A, which shows the caudal region of a representative treated embryo). Phosphohistone H3 (pH-H3)-positive cells were counted on transverse sections immediately anterior (B) and posterior (C) to the closure point. (D) Mitotic index was significantly elevated in the hindgut (Hg) and neural folds (Nf) of embryos treated with thymidine + adenine (asterisk indicates significant difference to controls; $P < 0.05$, *t*-test). Scale bars: A = 1 mm; B–C = 0.1 mm. $n =$ seven treated and nine control embryos with seven to eight sections analysed per embryo. (E) Foetal size at Day 13.5 (E13.5), as determined by measurement of crown–rump length, did not significantly differ between control litters and those exposed to supplemental nucleotides at Days 7.5–10.5, suggesting that long-term growth is not affected after cessation of treatment. Data are expressed as mean ± SEM. Number of foetuses analysed: controls = 22; thymidine only (Thy) = 13; thymidine + adenine = 39; thymidine + GMP = 21. Ade = adenine.

Birth defects are the leading cause of infant mortality in developed nations and cause long-term health problems in surviving children. Among these conditions neural tube defects are so far unique in being amenable to primary prevention. However, the existence of a subset of neural tube defects that are resistant to folic acid means that further reduction in the rate of neural tube defects is likely to require development of adjunct therapies to be used in combination with folic acid. Direct supplementation with nucleotide precursors represents an avenue for further investigation and in humans has been found to be possible by oral means, for example in infant formula (Singhal *et al.*, 2010). We hypothesize that maternal supplementation with nucleotide precursors could not only prevent some folic acid-resistant neural tube defects but potentially enhance the protection afforded by folic acid in responsive cases.

Funding

This work was supported by the Medical Research Council (J003794), Newlife Foundation (11-1206) and the Wellcome Trust (087525).

Supplementary material

Supplementary material is available at *Brain* online.

References

- Beaudin AE, Abarinov EV, Noden DM, Perry CA, Chu S, Stabler SP, et al. Shmt1 and *de novo* thymidylate biosynthesis underlie folate-responsive neural tube defects in mice. *Am J Clin Nutr* 2011; 93: 789–98.
- Blom HJ, Shaw GM, Den Heijer M, Finnell RH. Neural tube defects and folate: case far from closed. *Nat Rev Neurosci* 2006; 7: 724–31.
- Brook FA, Shum ASW, Van Straaten HWM, Copp AJ. Curvature of the caudal region is responsible for failure of neural tube closure in the curly tail (ct) mouse embryo. *Development* 1991; 113: 671–8.
- Burren KA, Savery D, Massa V, Kok RM, Scott JM, Blom HJ, et al. Gene-environment interactions in the causation of neural tube defects: folate deficiency increases susceptibility conferred by loss of *Pax3* function. *Hum Mol Genet* 2008; 17: 3675–85.
- Burren KA, Scott JM, Copp AJ, Greene ND. The genetic background of the curly tail strain confers susceptibility to folate-deficiency-induced exencephaly. *Birth Defects Res A Clin Mol Teratol* 2010; 88: 76–83.
- Cockroft DL. Dissection and culture of postimplantation embryos. In: Copp AJ, Cockroft DL, editors. *Postimplantation mammalian embryos: a practical approach*. Oxford: IRL Press; 1990. p. 15–40.
- Cogram P, Hynes A, Dunlevy LPE, Greene NDE, Copp AJ. Specific isoforms of protein kinase C are essential for prevention of folate-resistant neural tube defects by inositol. *Hum Mol Genet* 2004; 13: 7–14.
- Copp AJ. Relationship between timing of posterior neuropore closure and development of spinal neural tube defects in mutant (curly tail) and normal mouse embryos in culture. *J Embryol Exp Morphol* 1985; 88: 39–54.
- Copp AJ, Greene ND. Genetics and development of neural tube defects. *J Pathol* 2010; 220: 217–30.
- De Castro SC, Leung KY, Savery D, Burren K, Rozen R, Copp AJ, et al. (Grhl3) embryos are associated with alteration in folate one-carbon metabolism but are unlikely to result from diminished methylation. *Birth Defects Res A Clin Mol Teratol* 2010; 88: 612–18.
- De Castro SC, Malhas A, Leung KY, Gustavsson P, Vaux DJ, Copp AJ, et al. Lamin b1 polymorphism influences morphology of the nuclear envelope, cell cycle progression, and risk of neural tube defects in mice. *PLoS Genet* 2012; 8: e1003059.
- Dunlevy LPE, Chitty LS, Doudney K, Stojilkovic-Mikic T, Stanier P, et al. Abnormal folate metabolism in foetuses affected by neural tube defects. *Brain* 2007; 130: 1043–9.
- Fleming A, Copp AJ. Embryonic folate metabolism and mouse neural tube defects. *Science* 1998; 280: 2107–9.
- Greene ND, Copp AJ. Inositol prevents folate-resistant neural tube defects in the mouse. *Nat Med* 1997; 3: 60–6.
- Greene ND, Dunlevy LE, Copp AJ. Homocysteine is embryotoxic but does not cause neural tube defects in mouse embryos. *Anat Embryol (Berl)* 2003; 206: 185–91.
- Greene ND, Stanier P, Copp AJ. Genetics of human neural tube defects. *Hum Mol Genet* 2009; 18: R113–29.
- Gustavsson P, Greene ND, Lad D, Pauws E, de Castro SC, Stanier P, et al. Increased expression of Grainyhead-like-3 rescues spina bifida in a folate-resistant mouse model. *Hum Mol Genet* 2007; 16: 2640–6.
- Mills JL, Signore C. Neural tube defect rates before and after food fortification with folic acid. *Birth Defects Res Part A Clin Mol Teratol* 2004; 70: 844–5.
- Mitchell LE. Epidemiology of neural tube defects. *Am J Med Genet* 2005; 135C: 88–94.
- Momb J, Lewandowski JP, Bryant JD, Fitch R, Surman DR, Vokes SA, et al. Deletion of *Mthfd1l* causes embryonic lethality and neural tube and craniofacial defects in mice. *Proc Natl Acad Sci USA* 2013; 110: 549–54.
- Mosley BS, Cleves MA, Siega-Riz AM, Shaw GM, Canfield MA, Waller DK, et al. Neural tube defects and maternal folate intake among pregnancies conceived after folic acid fortification in the United States. *Am J Epidemiol* 2009; 169: 9–17.
- Narisawa A, Komatsuzaki S, Kikuchi A, Niihori T, Aoki Y, Fujiwara K, et al. Mutations in genes encoding the glycine cleavage system predispose to neural tube defects in mice and humans. *Hum Mol Genet* 2012; 21: 1496–503.
- Neumann PE, Frankel WN, Letts VA, Coffin JM, Copp AJ, Bernfield M. Multifactorial inheritance of neural tube defects: Localization of the major gene and recognition of modifiers in *ct* mutant mice. *Nat Genet* 1994; 6: 357–62.
- Parle-McDermott A, Pangilinan F, O'Brien KK, Mills JL, Magee AM, Troendle J, et al. A common variant in *MTHFD1L* is associated with neural tube defects and mRNA splicing efficiency. *Hum Mutat* 2009; 30: 1650–6.
- Ricks DJ, Rees CA, Osborn KA, Crookston BT, Leaver K, Merrill SB, et al. Peru's national folic acid fortification program and its effect on neural tube defects in Lima. *Rev Panam Salud Publica* 2012; 32: 391–8.
- Singhal A, Kennedy K, Lanigan J, Clough H, Jenkins W, Elias-Jones A, et al. Dietary nucleotides and early growth in formula-fed infants: a randomized controlled trial. *Pediatrics* 2010; 126: e946–53.
- Smithells RW, Sheppard S, Schorah CJ, Seller MJ, Nevin NC, Harris R, et al. Possible prevention of neural-tube defects by periconceptional vitamin supplementation. *Lancet* 1980; 1: 339–40.
- Stover PJ. One-carbon metabolism-genome interactions in folate-associated pathologies. *J Nutr* 2009; 139: 2402–5.
- Van Straaten HW, Copp AJ. Curly tail: a 50-year history of the mouse spina bifida model. *Anat Embryol (Berl)* 2001; 203: 225–37.
- Wald N, Sneddon J, Densem J, Frost C, Stone R, MRC Vitamin Study Res Group. Prevention of neural tube defects: results of the Medical Research Council vitamin study. *Lancet* 1991; 338: 131–7.
- Wlodarczyk BJ, Tang LS, Triplett A, Aleman F, Finnell RH. Spontaneous neural tube defects in splotch mice supplemented with selected micro-nutrients. *Toxicol Appl Pharmacol* 2006; 213: 55–63.